Clinical trials: Metastatic Digestive System Carcinoma
Hepatocellular Carcinoma
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein…
- Trial name
- BANTAM-01 (NCT06764316)
- Testing
- BAY 3547926, BAY 3547922, BAY 3713391
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 148 people
- Sponsor
- Bayer
Metastatic Pancreatic Cancer
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
This study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) [PAG] to NAB and GEM [AG] in participants with Stage IV previously untreated pancreatic ductal…
- Trial name
- NCT01839487
- Testing
- PEGPH20, Nab-paclitaxel, Gemcitabine
- Where
- 51 sites in United States
- Volunteers
- 279 people
- Sponsor
- Halozyme Therapeutics
Hepatocellular Carcinoma
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
- Trial name
- ATHENA (NCT06084884)
- Testing
- AZD5851
- Where
- 19 sites in United States, Japan and 1 more
- Volunteers
- 94 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
The purpose of this study is to determine the effect of CS-1008 in combination with irinotecan compared to irinotecan alone on Progression-Free Survival (PFS) in subjects with metastatic or advanced colorectal cancer (CRC) who…
- Trial name
- NCT00969033
- Testing
- CS-1008, irinotecan
- Where
- 9 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- Daiichi Sankyo
Colorectal Neoplasms, Advanced Metastatic Colorectal Cancer
Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)
Patients are being asked to participate in this study who have colorectal cancer that has come back after initial treatment. The investigators want to improve treatment in patients with this disease.
- Trial name
- NCT01909362
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- US Oncology Research
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Solid Tumor
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as…
- Trial name
- NCT03085914
- Testing
- Epacadostat, Pembrolizumab, Oxaliplatin
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Refractory Metastatic Colorectal Cancer, pMMR
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair…
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Trial name
- NCT05733611
- Testing
- RP2, RP3, atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Replimune, Inc.
Colorectal Carcinoma
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
The purpose of this study is to test how long participants with colorectal cancer live without progressive disease when being treated with IMC-1121B (ramucirumab) and the modified FOLFOX-6 chemotherapy.
- Trial name
- NCT00862784
- Testing
- IMC-1121B (ramucirumab), Oxaliplatin, Folinic acid
- Where
- 7 sites in Canada, Spain
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of YL202 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT07202364
- Testing
- YL202
- Where
- China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Colorectal Cancer
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for metastatic colorectal cancer.
- Trial name
- NCT00008281
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 134 sites in United States, Canada
- Sponsor
- Sanofi
Hepatocellular Carcinoma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic hepatocellular carcinoma patients treated with NGR-hTNF as single agent.
- Trial name
- NCT00484211
- Testing
- NGR-hTNF
- Where
- 3 sites in Italy
- Volunteers
- 40 people
- Sponsor
- AGC Biologics S.p.A.
Colorectal Cancer, Non-Small Cell Lung Cancer
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
- Trial name
- NCT05954871
- Testing
- GDC-1971, Osimertinib, Cetuximab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068…
- Conditions
- Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT06147037
- Testing
- FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
- Where
- 8 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable
- Trial name
- NCT07861425
- Testing
- ACE723
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Acepodia Biotech, Inc.
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician choice standard treatment in participants with human epidermal growth factor receptor 2 (HER2)-overexpression…
- Trial name
- NCT04714190
- Testing
- RC48-ADC, Paclitaxel injection, Irinotecan Hydrochloride Injection
- Where
- 52 sites in China
- Volunteers
- 351 people
- Sponsor
- RemeGen Co., Ltd.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.